Designed to transplant more organs
and improve outcomes
OrganOx metra is transforming liver transplantation, enabling functional assessment of donor organs prior to transplantation, reducing early allograft dysfunction and improving transplantation logistics, to the benefit of both transplant recipients and hospitals.1—4


With the OrganOx metra, the donor liver is continuously perfused with oxygenated blood, medications and nutrients at normal body temperature and near physiological pressures and flows. The metra is fully automated, easy-to-use and can preserve the donor organ in a functional state for up to 24 hours.1, †
MacRobert Award 2019
OrganOx was honoured to be shortlisted for the MacRobert Award in 2019; the UK's most prestigious prize for UK engineering innovation. Watch our finalist video here, highlighting the clinical impact of the metra:

Explore the normothermic machine perfusion scientific and clinical evidence base
Scientific and clinical evidence-
10th January 2023
OrganOx Enrols First US Patient for Post-Approval Study
Read more -
1st December 2022
OrganOx appoints John Liddicoat M.D. as Non-Executive Director to the Board
Read more -
11th May 2022
OrganOx announces partnership with Ochre Bio
Read more
-
12 - 17 Sep 2020
TTS Annual Congress
Read more -
22 - 25 Jun 2020
AOPO Annual Meeting
Read more -
30 - 30 May 2020
ATC Congress
Read more
References: 1. As demonstrated by a reduction in in Early Allograft Dysfunction from 30% (static cold storage) to 10% (metra). Nasralla D et al. Nature 2018; 557(7703):50–56. 2. Mergental H et al. Hepatology 2018; 68(1):(Suppl). 3. NICE Interventional procedures guidance (IPG636). Available at: https://www.nice.org.uk/guidance/ipg636. 4. Bral M et al. Liver Transpl 2019; 25(6):848–858.
† Disclaimer: metra® is FDA-approved for normothermic liver perfusion in the United States and can preserve the donor organ in a functional state for up to 12 hours.
UK/US MD-040-1-1 - September 2022